Related to this topic: Support | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Henoch-Schonlein Purpura (HSP)

Henoch-Schönlein purpura is an IgA-mediated, autoimmune, hypersensitivity vasculitis of childhood. The main clinical features are skin purpura, arthritis, abdominal pain, gastrointestinal bleeding, orchitis, and nephritis. The aetiology remains unknown.

Epidemiology
  • In the United Kingdom, the estimated annual incidence is 20 cases per 100,000 population.1
  • The peak prevalence is in children aged 3-10 years. It is rare in infants and young children.
  • The disease occurs mostly in the Winter months and the male-to-female ratio is 1.5-2:1. Whites are more affected than blacks.

Risk Factors

Associated conditions preceding Henoch-Schönlein purpura include:

Presentation
  • In one half to two thirds of children, an upper respiratory tract infection precedes the clinical onset by 1-3 weeks.
  • Generally, patients appear to be mildly ill, with low-grade fever.
  • Symmetrical erythematous macular rash, especially on the back of the legs, buttocks, and ulnar side of the arms.
  • Within 24 hours, the macules evolve into purpuric lesions, which may coalesce and resemble bruises.
  • Abdominal pain and bloody diarrhoea may precede the typical purpuric rash. Intussusception should then be considered (occurs in 2-3% of patients). Henoch-Schönlein purpura may also cause nausea and vomiting.
  • Arthralgias, especially knees and ankles. Joints may be swollen, tender, and painful but permanent deformity does not occur.
  • Renal involvement:
    • Affects 50% of older children and 25% of children under 2 years of age.
    • Less than 1% of patients progress to end stage renal disease.
    • Usually occurs within 3 months of disease onset.
    • There is usually no relationship between the severity of nephritis and the extent of the other manifestations of Henoch-Schönlein purpura.
    • Microscopic haematuria with mild-to-moderate proteinuria may occur.
    • Nephrotic syndrome may also occur.
    • Oliguria and hypertension are rare.
  • Scrotal involvement may mimic testicular torsion.
  • Neurological: headaches may occur.
Differential Diagnosis
  • Connective tissue diseases, e.g. SLE
  • Other causes of purpuric rash, e.g. thrombocytopenia
  • Other causes of glomerulonephritis
  • Acute hemorrhagic oedema of infancy is milder and occurs in infants younger than 2 years. The onset is sudden, with acute palpable purpura, bruises, and tender oedema of the limbs and face.3
Investigations
  • Urinalysis: haematuria; may also be proteinuria
  • Full blood count: may be raised white cell count with eosinophilia; normal or increased platelets
  • Raised ESR
  • Serum creatinine may be elevated in renal involvement
  • Serum IgA levels are often increased
  • Autoantibody screen: connective tissue diseases
  • Abdominal ultrasound: if gastrointestinal symptoms - for diagnosis intestinal obstruction
  • Barium enema: may be used to confirm and treat intussusception
  • Testicular ultrasound: assessment of possible torsion
  • Renal biopsy: if persistent nephrotic syndrome
Management
  • Henoch-Schönlein purpura is usually self-limiting and no form of therapy has been shown to appreciably shorten the duration of disease or prevent complications. Therefore treatment for most patients remains primarily supportive.
  • Non-steroidal anti-inflammatory drugs may help joint pain but should be used with caution in patients with renal insufficiency.
  • May require admission to hospital for monitoring of abdominal and renal complications.
  • Nephropathy: treated supportively. A variety of drugs (steroids, azathioprine, cyclophosphamide) and plasmapheresis have been used to prevent the progression of the renal disease but the results of trials have been inconsistent.4
  • Corticosteroids can ameliorate associated arthralgias and the symptoms associated with gastrointestinal dysfunction. There is no definitive evidence that corticosteroids affect the outcome of renal disease.
  • No controlled clinical trials have been performed with immunosuppressive drugs, although azathioprine or cyclophosphamide may be beneficial.4
  • Plasma exchange is used in the management of some adults with vasculitis and idiopathic rapidly progressive nephritis.4
Complications
  • Renal involvement occurs in 50% of older children but is only serious in approximately 10% of patients. Overall, 2-5% of cases progress to end stage renal failure. The renal prognosis is worse in older children and adults.
  • Other rare complications include myocardial infarction, pulmonary haemorrhage, pleural effusion, intussusception (in 2-3% of patients), gastrointestinal bleeding, bowel infarction, seizures, mononeuropathies.
  • Recurrence of symptoms and recurrence renal impairment may occur but recurrence of renal impairment is rare.
Prognosis
  • HSP is an acute self-limited illness and usually resolves without treatment, but may rarely lead to complications. Initial attacks of Henoch-Schonlein purpura can last several months. One third of patients have one or more recurrences.
  • Children younger than 3 years have a shorter, milder course and fewer recurrences.
  • The long-term prognosis of Henoch-Schönlein purpura is directly dependent on the severity of renal involvement.5


Document References
  1. Gardner-Medwin JM, Dolezalova P, Cummins C, et al; Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002 Oct 19;360(9341):1197-202. [abstract]
  2. Lane SE, Watts R, Scott DG; Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005 Aug;7(4):270-5. [abstract]
  3. Shetty AK, Desselle BC, Ey JL, et al; Infantile Henoch-Schonlein purpura. Arch Fam Med. 2000 Jun;9(6):553-6. [abstract]
  4. Tizard EJ; Henoch-Schonlein purpura. Arch Dis Child. 1999 Apr;80(4):380-3.
  5. Saulsbury FT; Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore). 1999 Nov;78(6):395-409. [abstract]

Internet and Further Reading
  • Bossart P; Henoch-Schonlein Purpura; eMedicine February 2007
Acknowledgements EMIS is grateful to Dr Colin Tidy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 2251
Document Version: 20
DocRef: bgp1227
Last Updated: 12 Jun 2007
Review Date: 11 Jun 2009

Patient Experience




















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site










Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page